Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
RESEARCH TOOLSreports
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.32Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 19, 2025
|% Change Since: -3.17%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in XPOVIO net product revenue and significant progress in clinical trials for myelofibrosis and endometrial cancer. However, challenges included a decrease in total revenue from licensing agreements, an increased gross-to-net discount, and a reduced cash position, signaling potential financial concerns. The overall sentiment is balanced with notable achievements offset by financial challenges.Company Guidance
During the call, Karyopharm Therapeutics provided guidance for 2025, focusing on key financial and operational metrics. The company expects total revenue to be between $140 million and $155 million, with U.S. XPOVIO net product revenue projected at $115 million to $130 million. R&D and SG&A expenses are estimated to range from $240 million to $255 million. The company plans to continue advancing its Phase 3 clinical trials, particularly the SENTRY Trial in myelofibrosis, aiming to complete enrollment in the first half of 2025 and announce top-line data in the second half. Karyopharm is also preparing for the potential launch of Selinexor in myelofibrosis, estimating peak U.S. revenue potential at $1 billion. They are exploring various financing and business development activities to extend their cash runway into 2026 and remain focused on driving XPOVIO revenue growth while managing costs effectively.XPOVIO Revenue Growth
XPOVIO net product revenue increased to $29.3 million in Q4 2024, up 16% compared to Q4 2023, indicating strong demand and performance despite competition.
Cost Reduction Achievements
Successful cost reduction initiatives resulted in a decrease in SG&A expenses for 2024 compared to 2023, delivering $12 million of annual savings.
Myelofibrosis Trial Progress
The Phase 3 SENTRY Trial in myelofibrosis is progressing well, with enrollment expected to complete in the first half of 2025 and top-line data anticipated in the second half of 2025.
Endometrial Cancer Trial Modifications
Updated the Phase 3 trial design for endometrial cancer following FDA recommendations, focusing on patients with pMMR tumors for potential new treatment options.
Global Demand and Reimbursement Approvals
Received multiple international reimbursement approvals for XPOVIO, increasing regulatory milestone payments and supporting global demand.
---
KPTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KPTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 19, 2025 | $0.63 | $0.60 | -4.76% |
| Nov 05, 2024 | $0.93 | $0.84 | -9.68% |
| Aug 06, 2024 | $0.87 | $0.84 | -3.45% |
| May 08, 2024 | $1.10 | $1.02 | -7.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Karyopharm Therapeutics (KPTI) report earnings?
Karyopharm Therapeutics (KPTI) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Karyopharm Therapeutics (KPTI) earnings time?
Karyopharm Therapeutics (KPTI) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KPTI EPS forecast?
KPTI EPS forecast for the fiscal quarter 2025 (Q1) is -0.27.
---